Valence 로고
인기
로그인
Loading data for AMRX — first visit, this takes a few seconds.

관심목록에 추가

Amneal Pharmaceuticals In...

NasdaqGS: AMRX · 실시간 가격 · USD
18.11
-0.08 (-0.44%)
종가 기준: Aug 17, 2026, 8:00 PM
18.28
-0.76%
애프터마켓: 7:34 PM

Amneal Pharmaceuticals Inc. (AMRX) Stock Price, Analysis & Data

-0.44%

데이터 없음

매수호가18.2
시가총액6.42B
매출 (ttm)3.12B
순이익 (ttm)157.36M
베타1.25
EPS (ttm)0.48
P/E (ttm)38.38
선행 P/E15.35
P/B (ttm)178.83
P/S (ttm)2.06
Earnings DateMay 4, 2026
매도호가18.16
거래량1,469,811
평균 거래량 (20일)2,034,704
시가18.51
전일 종가18.19
일중 범위17.95 - 18.57
52주 범위9.20 - 19.26
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

AMRX 소개

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and e...

[더 보기]
산업 Drug Manufacturers - Specialty & Generic
섹터 Healthcare
IPO 일자 May 7, 2018
직원 수 8,700
상장 거래소 NasdaqGS
티커 AMRX
웹사이트 https://www.amneal.com
전체 기업 정보

재무 실적

2025년 Amneal Pharmaceuticals의 매출은 3.02B로, 전년 2.79B 대비 8.05% 증가했습니다. 순이익은 72.06M로, -161.65% 감소했습니다.

재무제표

어닝 서프라이즈

Amneal Pharmaceuticals가 Jul 30, 2026에 분기 실적을 발표했습니다:
  • 매출 $796.2M 예상치 하회 $0, 및 9.89% 전년 대비 성장.
  • EPS 0.3 예상치 상회 0.07, 및 20.00% 전년 대비 성장.

    • 다음 실적 발표

    Amneal Pharmaceuticals Inc.의 실적 발표 예정일은 May 4, 2026, 장 마감 후입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1일 전 · Zacks

    ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up

    argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

    news image

    1일 전 · Zacks

    UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label

    United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

    news image

    1일 전 · StockStory

    3 Profitable Stocks That Fall Short

    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my...

    news image

    5일 전 · Zacks

    Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

    KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

    news image

    5일 전 · Zacks

    CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

    CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

    2 페이지 중 1